INTRODUCTION
Spinobulbar muscular atrophy (SBMA, also known as Kennedy's disease) is a progressive late-onset degenerative disorder of the motor neurons in the brainstem and spinal cord that affects only men (Kennedy et al., 1968) . SBMA is a member of the polyglutamine repeat disease family, which includes at least eight other disorders, including Huntington's disease (HD), dentatorubralpallidoluysian atrophy (DRPLA), and six forms of spinocerebellar ataxia (SCA). All of these diseases are caused by gain-of-function mutations characterized by expanded trinucleotide (CAG) repeats in exonic regions of DNA, and all result in late-onset, progressive neurodegeneration (Zoghbi and Orr, 2000) . In SBMA, the CAG repeat site is located in the androgen receptor (AR) gene and causes disease when the number of repeats is 40 or greater (La Spada et al., 1991) . Patients often display signs of mild feminization, likely due to partial loss of AR function. Although loss of AR function may contribute to disease (Thomas et al., 2006) , it is not sufficient for degeneration, as loss-of-function mutations to AR result in androgen insensitivity syndrome without signs of neuronal degeneration (Quigley et al., 1992) .
A central mystery in the field of polyglutamine disease research arises from the observation that the same mutation in nine different proteins results in nine different diseases; yet in each disease, different subsets of neurons are affected. This pattern occurs despite widespread and overlapping expression of the disease proteins, suggesting that the inherent toxicity of the expanded polyglutamine is not the sole basis of toxicity. Indeed, in SBMA mouse models, expression of polyglutamineexpanded fragments of AR results in widespread neuronal degeneration, a phenotype that is not dissimilar from that observed in transgenic animal models expressing fragments of other polyglutamine-expanded proteins (Abel et al., 2001) . In contrast, models employing full-length polyglutamine-expanded AR protein more accurately reflect the human disease, displaying restricted symptoms, lower motor neuron specificity in degeneration, and gender specificity (Chevalier-Larsen et al., 2004; Sopher et al., 2004) .
These findings highlight the importance of protein context in polyglutamine disease, and raise the question of the role of protein domains other than the polyglutamine tract in toxicity. It is not clear whether the mutation results in the formation of novel, toxic interactions, or whether the mutation alters the normal, native interactions of the polyglutamine-containing protein in such a way as to result in neurotoxicity. Though these possibilities are not mutually exclusive, recent studies in SCA1, SCA7, and SCA17 have provided evidence in favor of a model in which the normal function of the disease protein is tied to the mechanism of pathogenesis (Emamian et al., 2003; Friedman et al., 2007; Helmlinger et al., 2006; Lim et al., 2008; McMahon et al., 2005; Palhan et al., 2005; Tsuda et al., 2005) . More direct evidence that native interactions may mediate toxicity comes from animal models in which overexpression of nonexpanded ataxin-1 or AR results in pathology resembling SCA1 and SBMA, respectively (Fernandez-Funez et al., 2000; Monks et al., 2007) .
In the majority of polyglutamine diseases, neither the primary function nor the native interactors of the disease proteins are well known. SBMA is an exception in that the disease protein has a well-characterized role as a ligand-dependent transcription factor. AR is a member of the nuclear hormone receptor (NHR) superfamily and resides in the cytoplasm when inactive. A number of events occur upon ligand binding, the final result of which is AR-mediated activation or repression of target genes. These ligand-induced events include several posttranslational modifications, nuclear translocation, and DNA binding. These changes occur in concert with conformational changes that result in the exposure of two coregulator interaction surfaces, termed activation function-1 (AF-1) and activation function-2 (AF-2). Ligand binding to polyglutamine-expanded AR is a requisite step in disease pathogenesis. Indeed, there is now incontrovertible evidence from animal model studies as well as human studies that gender specificity in SBMA is due to higher levels of circulating androgens in males (Katsuno et al., 2002; Takeyama et al., 2002) .
Although the basis of the toxic gain of function imparted by the polyglutamine expansion remains unknown, the ligand dependence of SBMA implies that ligand-induced alterations of AR play important roles in toxicity. In this study, we used a Drosophila model to test the hypothesis that SBMA is mediated by ligand-induced alterations in native AR interactions. First, we present evidence that nuclear translocation of AR is necessary, but not sufficient, for toxicity, demonstrating that ligand-induced modifications of AR (beyond nuclear translocation) are required for pathogenesis. Second, we show that DNA binding of polyglutamine-expanded AR is required for toxicity, indicating that the native DNA-binding function of AR is critical to pathogenesis. Third, we use a genetic screen to identify modifiers of SBMA toxicity, which reveal a pattern of AF-2-based coregulators that genetically interact with polyglutamine-expanded AR. Pursuing this finding, we show rescue of polyglutamine-expanded AR toxicity through two independent point mutations designed to disrupt the AF-2 coregulator interaction surface. To more precisely define the degenerative phenotype associated with polyglutamine-expanded AR toxicity, we used expression profile analysis. This analysis confirmed that interruption of either the AF-2 or DNA binding domains robustly suppressed this molecular phenotype. In addition, analysis of the molecular phenotype of flies expressing wild-type AR revealed the same (albeit weaker) molecular phenotype as polyglutamine-expanded AR, indicating that amplification of normal AR function may underlie the toxicity of polyglutamine-expanded AR. Finally, we investigated the AR coregulator ortholog limpet, a gene identified in our genetic screen, as proof of principle that polyglutamine-expanded AR toxicity is mediated via native function of the AF-2 binding surface following DNA binding.
RESULTS

Expression of Polyglutamine-Expanded AR in Drosophila Results in Toxicity
In order to investigate the contributions of AR interactions to polyglutamine-expanded AR toxicity, we used a Drosophila model of SBMA. Although human AR has no direct ortholog in flies, the NHR system is well conserved (King-Jones and Thummel, 2005) . This conservation is reflected in the domain architecture of Drosophila nuclear receptors, including AF-1 and AF-2 coregulator interaction domains that bind to conserved motifs in nuclear receptor coregulators. It was previously demonstrated that human AR expressed in Drosophila tissues translocates to the nucleus and activates transcription of an ARE-GFP reporter transgene in response to dihydrotestosterone (DHT) (Takeyama et al., 2002) . This cross-species transactivational capacity reflects the fact that human AR interacts with endogenous Drosophila coactivators and corepressors; indeed, genetic modulation of Drosophila homologs of mammalian AR coregulators can modify the transactivational capacity of AR in vivo (Takeyama et al., 2004) .
When human AR of varying polyglutamine lengths is expressed using the GAL4-UAS system (Brand and Perrimon, 1993) , flies develop polyglutamine length-and ligand-dependent degenerative phenotypes, thus recapitulating two fundamental features of SBMA (Pandey et al., 2007; Takeyama et al., 2002) . To assess toxicity in an externally visible neuronal tissue, we expressed AR in the eye using the glass multimer reporter driver (GMR-GAL4), which leads to transgene expression in photoreceptor neurons and accessory pigment cells in developing eye discs (Moses and Rubin, 1991) . Whereas flies expressing AR show no eye phenotype when reared on normal food, flies reared on food containing DHT exhibit a degenerative phenotype that is limited to the posterior margin of the eye ( Figure 1A ). The severity of the phenotype is also polyglutamine-length dependent, with AR52Q-expressing flies showing severe ommatidial pitting, disorganization, and fusion, as well as abnormal and supernumerary interommatidial bristles. In contrast, AR12Q-expressing flies show only mild ommatidial and bristle phenotypes when the transgene is expressed at equivalent levels ( Figures  1A-1C ). Confocal imaging of eye discs confirmed that AR undergoes DHT-dependent nuclear translocation in vivo. This analysis also revealed diffuse nuclear accumulation of AR and the formation of small nuclear and cytoplasmic puncta that were particularly prominent with polyglutamine-expanded AR ( Figure 1D ).
The polyglutamine length-and DHT-dependence of SBMA is recapitulated in several larval tissues. For example, using the larval salivary gland driver (fkh-GAL4) (Andrew et al., 2000) , expression of polyglutamine-expanded AR results in a dramatic reduction of salivary gland cell size ( Figures 1E and 1F ). Larvae expressing AR in motor neurons under the control of the D42-GAL4 driver (Yeh et al., 1995) also show polyglutamine lengthand DHT-dependent defects in locomotor ability as measured (A) Drosophila females expressing AR in eyes using GMR-GAL4 were raised in medium containing vehicle or DHT and adult eye phenotypes were assessed by light microscopy.
(B) Blinded scoring of the external eye phenotypes in (A) using a quantitative scoring system (Pandey et al., 2007) . (C) Western blot showing levels of AR expression for AR12Q-and AR52Q-expressing flies shown in (A).
(D) Pupae expressing AR in eyes using GMR-GAL4 were raised in medium with or without DHT and whole-mount preparations of eye discs were immunostained for lamin (blue) and AR (green). Phalloidin (red) was used to stain F-actin. Samples were examined by confocal microscopy. (E and F) Third instar larvae expressing AR in the salivary gland using fkh-GAL4 were dissected and stained with DAPI (blue) and phalloidin (red). Overall gland size is shown in (E), and cell size is shown in (F). Phalloidin staining was used to delineate cell boundaries and determine cell size. Scale bar, 50 mm. (G) Third instar larvae expressing AR12Q or AR52Q using D42-GAL4 were assessed for their ability to travel distances along the surface of an agar plate.
(H and I) Larvae expressing AR52Q using OK371-GAL4 were raised in medium containing vehicle or DHT, dissected as third instar wandering larvae, and stained using the postsynaptic marker discs large (DLG, green) and the presynaptic marker HRP (red). Type 1B boutons were counted at muscle 4. Scale bar, 10 mm.
(J) Female flies expressing AR12Q using GMR-GAL4 were raised on medium containing DHT. Each line shown represents an independent transformant line.
by larval crawling assay, indicating a significant functional deficit ( Figure 1G ). In addition, the number of type 1B boutons at the larval neuromuscular junction (NMJ) is significantly decreased in a DHT-dependent manner when polyglutamine-expanded AR is expressed using the motor neuron driver OK371-GAL4 (Mahr and Aberle, 2006) (Figures 1H and 1I) . Importantly, we noticed that expression of wild-type polyglutamine-length AR at high levels results in a degenerative phenotype that is indistinguishable from that caused by polyglutamine-expanded AR ( Figures 1J and 1K ). This is reminiscent of the SBMA-like phenotype associated with high-level expression of wild-type AR in mice (Monks et al., 2007) . The dose-dependent toxicity of wild-type AR suggests the possibility that amplification of native AR function may contribute to the toxicity of polyglutamine-expanded AR.
Nuclear Translocation of Polyglutamine-Expanded AR Is Necessary for Toxicity The observation that ligand binding to AR is required for pathogenesis suggests a model in which nontoxic AR is converted to a proteotoxin through ligand-induced events. The first major event to occur upon ligand binding is translocation of AR to the nucleus. In most polyglutamine diseases, the primary site of cellular toxicity is thought to be the nucleus (Klement et al., 1998; Montie et al., 2009; Peters et al., 1999; Saudou et al., 1998; Takeyama et al., 2002) , although cytoplasmic toxicity may also contribute (Hodgson et al., 1999; Morfini et al., 2006; Szebenyi et al., 2003) . In the case of SBMA, whether nuclear translocation of polyglutamine-expanded AR is both necessary and sufficient for toxicity has not been examined in vivo.
AR has three major domains ( Figure 2A ): (1) an N-terminal transactivation domain (NTD) that contains AF-1 and serves as a coregulator interaction surface, (2) a DNA-binding domain (DBD) that binds regulatory elements in AR-regulated promoters, and (3) a C-terminal ligand-binding domain (LBD) that binds testosterone or DHT and also harbors a second coregulator interaction surface (AF-2). Bridging the DBD and LBD is a flexible hinge domain that harbors a bipartite nuclear localization sequence (NLS). To address the necessity of nuclear translocation, we generated two AR constructs designed to remain in the cytoplasm even in the presence of DHT (Figure 2A ). In the first construct, we used phosphomimetic substitutions of serines 210 and 790 (AR65Q SS/DD) that prevent DHT binding to AR (Palazzolo et al., 2007) . In the second construct, we mutated residues K632 and K633 (AR73Q KK/AA) in the NLS of AR; these substitutions markedly alter DHT-induced nuclear translocation . COS-1 cells transfected with these constructs showed that the SS/DD and KK/AA mutations each caused AR to remain in the cytoplasm even in the presence of DHT (Figures S1A and S1B available online).
In order to investigate whether these cytoplasmic AR mutants cause toxicity in vivo, we generated transgenic Drosophila lines that express these proteins under the control of the GAL4-UAS system. We first confirmed that these modified AR proteins resist DHT-induced nuclear translocation in vivo in Drosophila by expressing the AR transgenes with the larval salivary gland driver fkh-GAL4. Salivary glands provide an ideal model to assess subcellular localization of proteins in Drosophila due to their highly ordered histoarchitecture and high ratio of cytoplasm to nucleus. Using fkh-GAL4, we found that whereas AR52Q showed nuclear localization, AR65Q SS/DD and AR73Q KK/AA remained in the cytoplasm despite the presence of DHT in the larval medium ( Figure 2C ).
In order to test the toxicity of these constructs in a neuronal tissue, we next expressed the AR transgenes using GMR-GAL4. As previously shown, expression of AR52Q in the eye resulted in a degenerative phenotype in a DHT-dependent manner (Figures 2B and 2D) . In contrast, eyes expressing AR65Q SS/DD or AR73Q KK/AA showed no degenerative phenotype even in the presence of DHT, despite high expression of AR (Figures 2B, 2D, and S2A). Consistent with prior reports (Montie et al., 2009; Takeyama et al., 2002) , these results indicate that nuclear translocation of polyglutamine-expanded AR is necessary for toxicity.
Nuclear Translocation of Polyglutamine-Expanded AR Is Not Sufficient for Toxicity
In order to address whether nuclear translocation of polyglutamine-expanded AR is sufficient for toxicity, we designed AR constructs that translocate to the nucleus in a DHT-independent manner, thereby dissociating nuclear translocation from ligand binding. To this end, we fused the SV40 NLS to either the C or N terminus of AR ( Figure 2A ). As an additional control, we fused an NLS to the AR65Q SS/DD protein that is unable to bind DHT. COS-1 cells transfected with AR65Q-NLS or NLS-AR65Q SS/DD show AR localized to the nucleus even in the absence of DHT (Figures S1C and S1D). In addition, AR65Q-NLS retained its transactivation ability in response to DHT as measured by an ARE-luciferase reporter, though only at about 50% of AR65Q ( Figure S1E ). As expected, NLS-AR65Q SS/DD did not activate transcription, due to its inability to bind DHT.
We next made transgenic Drosophila carrying UAS-AR65Q-NLS and UAS-NLS-AR65Q SS/DD. After confirming that AR65Q-NLS and NLS-AR65Q SS/DD translocate to the nucleus in the absence of DHT in vivo using fkh-GAL4 ( Figure 2E ), we expressed these transgenes in the eye using GMR-GAL4 ( Figures 2F and S2B ). Expression of AR65Q-NLS or NLS-AR65Q SS/DD did not cause toxicity in the absence of DHT, indicating that nuclear translocation of polyglutamine-expanded AR is not sufficient for toxicity. However, once the AR65Q-NLS animals were exposed to DHT, they developed the characteristic SBMA eye phenotype, demonstrating that DHT binding to AR provides the critical step in the conversion of polyglutamineexpanded AR from a nontoxic to a toxic molecule (Figures 2B and 2F) . An Intact DNA-Binding Domain Is Required for Polyglutamine-Expanded AR Toxicity Having determined that the role of DHT in SBMA is not simply to effect translocation of AR to the nuclear compartment, but also to modify nuclear AR, we hypothesized that AR's function as a DNA-binding transcription factor might play a role in pathogenesis. To investigate this hypothesis, we introduced a mutation to the AR DBD (A574D) that blocks the ability of AR to bind DNA without disrupting its ligand-binding ability (Brü ggenwirth et al., 1998) .
AR65Q A574D showed normal DHT-induced nuclear translocation in vitro ( Figure S3 ), although transactivation capacity was severely disrupted, as predicted due to the inability of the mutated AR to bind DNA ( Figure 3A ). Strikingly, transgenic flies expressing AR52Q A574D using GMR-GAL4 showed no degenerative phenotype even in the presence of DHT, indicating that of Drosophila larvae expressing AR using fkh-GAL4. Larvae were raised in medium containing DHT and processed for immunocytochemistry. AR was detected with anti-AR antibody (green) and nuclei were stained with DAPI (blue). Scale bar, 50 mm. (D) Drosophila females expressing AR in eyes using GMR-GAL4 were raised in medium containing vehicle or DHT and adult eye phenotypes were assessed by light microscopy. (E) Salivary glands of Drosophila larvae expressing AR using fkh-GAL4. Larvae were raised in medium containing ethanol and processed for immunocytochemistry as in (C). Scale bar, 50 mm. (F) Drosophila females expressing AR in eyes using GMR-GAL4 were raised in medium containing vehicle or DHT and adult eye phenotypes were assessed by light microscopy. See also Figures S1 and S2.
the A574D mutation abolished the toxicity of polyglutamineexpanded AR despite nuclear localization of AR and high transgene expression ( Figures 3B-3D , S2C, and S2D). Supporting this result, flies expressing polyglutamine-expanded AR with the A574D mutation showed no larval crawling defect when AR was expressed in motor neurons ( Figure 3E ). Additionally, introduction of the A574D mutation resulted in salivary gland cell size that was indistinguishable from AR52Q without DHT (Figures 3F and 3G) . These results indicate that the native DNA-binding function of AR is critical for pathogenesis.
AF-2-Interacting Coregulators Modify the Toxicity of Polyglutamine-Expanded AR
In the normal life cycle of AR, DNA binding is followed by the recruitment of coregulators (either corepressors or coactivators) that associate with AR at target promoters (Heinlein and Chang, 2002) . We hypothesized that coregulator binding, an event immediately downstream of DNA binding, might play a role in pathogenesis.
In order to investigate the role of AR coregulators in SBMA, we performed a candidate-based genetic screen for modifiers of (B) Salivary glands of Drosophila larvae expressing AR using fkh-GAL4. Larvae were raised in medium containing DHT and processed for immunocytochemistry. AR was detected with anti-AR antibody (green) and nuclei were stained with DAPI (blue). Scale bar, 50 mm.
(C) Drosophila females expressing AR in eyes using GMR-GAL4 were raised in medium containing DHT and adult eye phenotypes were assessed by light microscopy.
(D) Blinded scoring of the external eye phenotypes in (C) using a quantitative scoring system. (E) Third instar larvae expressing AR using the motor neuron driver D42-GAL4 were assessed for their ability to travel distances along the surface of an agar plate.
(F and G) Third instar larvae expressing AR in the salivary gland using fkh-GAL4 were dissected and stained with DAPI (blue) and phalloidin (red). Overall gland size is shown in (F), and cell size is shown in (G). Phalloidin staining was used to delineate cell boundaries and determine cell size. Scale bar, 50 mm. **p < 0.01 in all panels. n.s., not significant. Figures S4A and S4B ). These modifiers included some coregulators with obvious mechanisms of enhancement, including Pat1 and Pten, which normally function to inhibit AR nuclear translocation. The mechanism for other modifiers was less clear, although there was an interesting pattern among the hits because seven of them relate to the (Palvimo et al., 1996) Dl RELA RELA competes for AR coactivators (Palvimo et al., 1996) Ets96B ETV5 ETV5-AR interaction represses metalloproteinase expression (Schneikert et al., 1996) Fkh FOXH1 FOXH1 blocks DHT-induced AR nuclear foci Groucho AES AES interacts with basal transcriptional machinery (Yu et al., 2001) (Liao et al., 2003) wts LATS2 LATS2 decreases N/C interaction, requires AF-2 X EMS mutation enhances enhances, p < 0.05 (Powzaniuk et al., 2004) Seventy-three previously described AR coregulator genes were investigated for the existence of Drosophila orthologs. We identified 61 putative orthologs and obtained RNAi lines for these genes from the Vienna Drosophila RNAi Center. RNAi lines were tested for their ability to modify the SBMA fly phenotype. Shown are 19 hits from the screen that dominantly modified the AR52Q eye phenotype. Mammalian orthologs and mechanisms of AR interaction are shown. As indicated, seven of these hits were found to have AF-2-based interactions. These seven hits were validated in motor neurons by larval crawling assay, as well as with alternate alleles (classical alleles or aneuploid aberrations) in the eye. See also Figure S4 .
function of the AF-2 domain of AR. Specifically, CycD, gskt, jbug, Lmpt, Rad9, Smr, and wts (putative Drosophila orthologs of CCND1, GSK3B, FLNA, four-and-a-half LIM domains 2 [FHL2], RAD9, NCOR1/2, and LATS2, respectively) each play a role in AF-2 interactions, either by binding AF-2 directly or by modifying the AF-2-based interaction with the NTD (Table 1) . To confirm the specificity of these hits and to rule out off-target effects due to RNAi, we confirmed the effects of these AF-2-related hits in three additional contexts. First, we confirmed that classical alleles and aneuploid aberrations of these same genes would similarly enhance the AR52Q eye phenotype ( Figure S4C ). Second, after verifying that RNAi knockdown had no effect on larval crawling ability when expressed in motor neurons in the absence of AR52Q, we showed that these RNAi lines enhanced the AR52Q larval crawling defect in 6/7 cases (Table 1 , Figures S4D and  S4E ). Third, we showed that the RNAi lines did not enhance the AR52Q eye phenotype nonspecifically, by crossing RNAiexpressing lines to an unrelated disease model of inclusion body myopathy associated with Paget's disease of bone and frontotemporal dementia (IBMPFD) that shows a modifiable degenerative eye phenotype (Ritson et al., 2010 ) (data not shown).
A Functional AF-2 Binding Site Is Required for Toxicity AF-2 is a ligand-dependent hydrophobic surface flanked by opposing charged residues, K720 and E897 ( Figure 4A ). This surface is highly conserved across steroid hormone receptors and across species, and in most cases serves as a binding pocket for the LxxLL motifs of steroid receptor coactivator (SRC) family members (He et al., 1999) . Unlike other steroid hormone receptors, however, the AF-2 of AR binds an additional motif, defined as FxxLF, with higher affinity (Dubbink et al., 2004; He et al., 2001 He et al., , 2004 . The FxxLF motif is found in a small number of coregulators, as well as in the N terminus of AR, which allows for an intra-or intermolecular interaction between the NTD and AF-2 domains of AR. Current models propose that AF-2 binds the NTD FxxLF motif when AR is mobile, and that the NTD/AF-2 interaction is lost upon AR binding to DNA, rendering AF-2 optimally accessible to coregulators (van Royen et al., 2007) .
Because our targeted RNAi screen highlighted the importance of coregulator interactions with AF-2, we next investigated the role of AF-2 function in polyglutamine-expanded AR toxicity by taking advantage of three well-characterized mutations that disrupt AF-2-based interactions without influencing protein stability. The first, E897K, reverses the charge of one of the two charge clamp residues in AF-2, thereby abolishing both LxxLL-and FxxLF-mediated interactions (He et al., 1999) ( Figure 4A ). The second, K720A, which neutralizes the charge of the other charge clamp residue in AF-2, partially impairs AF-2 function by severely disrupting LxxLL-mediated interactions and decreasing FxxLF-based interactions by approximately 50% (Dubbink et al., 2004; He et al., 1999) . The third, G21E, located two amino acids from the FxxLF sequence in the NTD, blocks the NTD/AF-2 interaction without affecting AF-2 structure (Callewaert et al., 2003) . Neither E897K nor K720A alters the equilibrium binding affinity for ligand (He et al., 1999) .
In COS-1 cells, AR E897K, K720A, and G21E showed DHTinduced nuclear translocation, similar to wild-type AR ( Figures   S5A and S5B) . Luciferase-based transactivation assays indicated that while K720A and G21E mutants showed unaltered transactivation capacity, the activity of AR E897K was modestly decreased ( Figure 4C ). When expressed in vivo using fkh-GAL4, we found that all three mutant proteins translocated to the nucleus in response to DHT ( Figure 4B) . Importantly, the AF-2 mutations E897K and K720A strongly suppressed the phenotype caused by expression of polyglutamine-expanded AR in salivary gland cells ( Figures 4B, S5C, and S5D) . In contrast, the G21E mutation had no impact on salivary gland phenotype ( Figure 4B ).
We next tested the toxicity of these mutant proteins using GMR-GAL4. We found that introduction of the E897K mutation abolished the degenerative eye phenotype, indicating that complete disruption of AF-2 binding eliminates the toxicity of polyglutamine-expanded AR despite high levels of AR expression ( Figures 4E, S2C , S2D, and S5E). The K720A mutation also suppressed degeneration, confirming that both LxxLLand FxxLF-based binding to AF-2 are critical mediators of toxicity. In contrast, the G21E mutation had no discernable impact on the eye phenotype. This latter result argues that impaired coregulator interactions with AF-2, rather than impaired NTD binding to AF-2, underlie the suppressive effect of E897K and K720A mutations.
To corroborate the suppression seen by the K720A and E897K mutations, we next used the driver elav-GAL4, which drives transgene expression in all neurons. Whereas expressing AR52Q with elav-GAL4 resulted in early larval lethality, introducing the AF-2 mutations E897K or K720A resulted in increased viability, as evidenced by more flies surviving to the pupal stage ( Figures 4D and S5F ). When expressed in motor neurons with D42-GAL4, the E897K and K720A mutations also significantly suppressed the larval crawling defect seen in AR52Q flies ( Figure 4F ). In addition, AF-2 mutations suppressed the NMJ bouton phenotype, resulting in a significantly increased number of synaptic boutons, whereas the G21E mutation had no effect on this phenotype ( Figures 4G and 4H) . These results confirm the suppression observed in the eye while extending the findings to the cell type most affected in the human disease.
Expression Profile Analysis of AR Mutants Reveals the Molecular Phenotype of Eye Degeneration
Though the rescue of eye degeneration we observe with mutations to the DNA-binding domain or AF-2 domain is robust, and we have corroborated the findings in other tissues, we felt it would be valuable to generate a molecular phenotype to serve as an objective, quantifiable assay of degeneration. Using GMR-GAL4 to drive transgene expression in the eye, we used Affymetrix arrays to profile gene expression changes in flies expressing wild-type AR, polyglutamine-expanded AR, or polyglutamine-expanded AR with mutations affecting the DBD or AF-2. One-hundred and forty-nine genes were identified whose expression significantly changed in concert with ligand-induced degeneration in AR52Q-expressing flies, representing a molecular signature of degeneration ( Figures 5A and S6 , Table S1 available online). Hierarchical cluster analysis revealed strong correlation between this molecular readout and visual inspection of eye morphology (Figures 5A and 5B ). Principal components (B) Salivary glands of Drosophila larvae expressing AR using fkh-GAL4. Larvae were raised in medium containing DHT and processed for immunocytochemistry. AR was detected with anti-AR antibody (green) and nuclei were stained with DAPI (blue). Scale bar, 50 mm. (C) HEK293T cells were transfected with indicated AR constructs together with both the luciferase pARE-E1b-Luc and the b-galactosidase pCMVb reporter constructs. AR transactivation was measured in the presence and absence of DHT by luciferase assay and normalized to b-galactosidase activity. (D) Viability assay of Drosophila expressing indicated AR transgenes using elav-GAL4. Crosses were performed in medium containing DHT. The number of pupae from each 131 cross was counted and normalized to lacZ. Expression of AR52Q resulted in larval lethality, whereas E897K or K720A mutations increased survivability to the pupal stage. (E) Drosophila females expressing AR in eyes using GMR-GAL4 were raised in medium containing DHT and adult eye phenotypes were assessed by light microscopy. Left, AR constructs with 12Q. Right, AR constructs with expandedQ (AR52Q WT, AR66Q E897K, AR72Q K720A, AR65Q G21E). See Figure S5E for phenotype severity scores.
analysis showed that introduction of the E897K and A574D mutations reverted the molecular phenotype back to a pattern that is indistinguishable from AR12Q or AR52Q without ligand ( Figure 5C ). The K720A mutation partially reversed the molecular phenotype observed in the AR52Q flies +DHT, reflecting the milder suppression observed in these eyes when scored according to the severity of their external degenerative phenotype.
For the purpose of our study, we used expression profiles as a means of quantifying eye degeneration in our model. We caution against making too much of the identity of the individual genes whose expression is changed because the molecular phenotype that accompanies eye degeneration is likely dominated by secondary gene expression changes that are a consequence rather than a cause of degeneration. Nevertheless, we recognized the possibility that embedded within these expression profiles are some gene expression changes that are primarily due to AR binding. To address this possibility, we performed promoter analysis, which found no evidence of enrichment of genes containing AR binding sites among the DHT-responsive gene set (data not shown). Similarly, promoter analysis showed no enrichment for genes that are responsive to endogenous NHRs such as the ecdysone receptor (data not shown). These results suggest that although the molecular phenotype captured by our expression profiling can be used to quantify neurodegeneration in the adult eye, secondary gene changes are likely to obscure primary gene changes that occurred in the first steps of pathogenesis.
In addition to corroborating our visual inspection with respect to E897K, A574D, and K720A mutations and toxicity, the expression profile analysis also revealed that AR12Q +DHT caused nearly the same molecular signature as AR52Q +DHT, although the degree of expression level changes was generally weaker in AR12Q compared with AR52Q ( Figures 5A and S6 ). This observation is consistent with a model in which amplification of normal AR function may underlie the toxicity of polyglutamine-expanded AR. Indeed, as described above, expression of AR12Q in fly eyes can also result in degeneration when expressed at very high levels.
Modification of the SBMA Phenotype by the FxxLFContaining Coregulator limpet Is Dependent on AF-2
The strong suppression observed in the E897K mutants (which eliminates FxxLF-based interactions), along with the milder suppression observed in the K720A mutants (which merely decreases FxxLF-based interactions), implicated FxxLF-based coregulator interactions as playing a significant role in toxicity. Based on our genetic screen (Table 1) , we further examined the identity of our genetic modifiers in the context of FxxLFbased AF-2 interactions. Although some of these modifiers are not known to interact with AF-2 directly and not all contain FxxLF motifs, the AR coregulator FHL2, the human ortholog of Drosophila limpet, interacts with AF-2 directly via an FxxLF motif (Hsu et al., 2003) . FHL2/limpet is well conserved between fly and human (56.4% similarity, 74.4% identity), including the FxxLF motif ( Figure S7A) , and is one of a family of LIM domain-containing proteins, several of which are known to play a role in motor neuron development (Bhati et al., 2008) . The exact mechanism whereby FHL2 modifies AR transactivation is unknown, although LIM domain-containing proteins have been found to act as bridging molecules between transcription factors, suggesting that they may act as scaffolds in the assembly of transcriptional complexes (Wadman et al., 1997) . Thus, limpet provided a good candidate for further investigation, given that it may act to positively or negatively regulate the assembly of AF-2 complexes.
We therefore performed epistasis experiments to examine the ability of limpet to modify the toxicity of polyglutamine-expanded AR. Though RNAi knockdown of limpet in the Drosophila eye using GMR-GAL4 results in no externally visible phenotype in flies without the mutant AR transgene, limpet knockdown in flies expressing AR52Q enhanced the AR52Q degenerative eye phenotype ( Figures 6A, 6C , 6M, S7B, and S7C). Similarly, a classical P-element allele (Lmpt GE27535 ) of limpet enhanced the AR52Q phenotype ( Figures 6B, 6C , 6M, and S7B). A chromosomal duplication that produces two copies of the limpet gene (Dp(3;3)st + g18) (Tearle et al., 1989) suppressed the AR52Q phenotype, suggesting that depletion of limpet by AR contributes to toxicity ( Figures 6C, 6D , 6M, and S7B). This suppression was confirmed through expression profile analysis in which we determined that 46% of the gene expression changes that accompanied ligand-dependent degeneration in AR52Q flies were completely reversed by limpet duplication ( Figure 6N) .
Interestingly, although genetic manipulation of limpet did not modify the mild phenotype of flies expressing AR12Q at moderate levels (data not shown), limpet alleles did modify the more severe phenotype of flies expressing AR12Q at very high levels ( Figures 6E-6H and 6M) , suggesting that the molecular pathophysiology of high-expressing AR12Q flies is related to that of AR52Q flies. Importantly, limpet knockdown did not modify the phenotype of AR66Q E897K, indicating that the enhancement by limpet RNAi requires a functional AF-2 binding surface ( Figures 6I and 6J ). In addition, limpet duplication did not suppress the degenerative phenotype caused by pure polyglutamine protein (127Q) (Kazemi-Esfarjani and Benzer, 2000) , demonstrating that increased levels of limpet are not globally protective, but instead show a specific genetic interaction with AR ( Figures 6K and 6L) . These results are consistent with a model in which polyglutamine-expanded AR causes toxicity through AF-2-based interactions with coregulators.
DISCUSSION
In this study, we investigated the basis for the toxicity of polyglutamine-expanded AR by systematically interrogating liganddependent modifications of this NHR. We showed that nuclear (F) Third instar larvae expressing AR using the motor neuron driver D42-GAL4 were assessed for their ability to travel distances along the surface of an agar plate. (G and H) Larvae expressing AR using the motor neuron driver OK371-GAL4 were raised in medium containing vehicle or DHT, dissected as third instar wandering larvae, and stained using the postsynaptic marker discs large (DLG, green) and the presynaptic marker HRP (red). Type 1B boutons were counted at muscle 4. Scale bar, 10 mm. **p < 0.01 in all panels. Bars, mean + SEM in all panels. See also Figures S2 and S5. translocation of polyglutamine-expanded AR is necessary, but not sufficient, for toxicity and that DNA binding is required for toxicity. Insight from a genetic screen indicated that native interactions, those mediated by the AF-2 domain in particular, play a key role in toxicity. This suspicion was confirmed by our results indicating that toxicity is dependent upon a functional AF-2 binding surface. Specifically, we demonstrated that K720A and E897K mutations to the AF-2 coregulator interaction surface attenuated polyglutamine-expanded AR toxicity, whereas interruption of the NTD/AF-2 interaction had no effect. In the majority AR52Q  AR52Q  AR52Q  AR52Q  AR52Q  AR52Q  AR52Q  AR52Q   AR66Q E897K  AR66Q E897K  AR66Q E897K  AR52Q A574D  AR52Q A574D  AR52Q A574D   AR12Q  AR12Q  AR12Q  AR12Q   AR72Q K720A  AR72Q K720A  AR72Q K720A  AR72Q K720A   DHT  DHT  DHT  DHT  DHT  DHT  DHT  DHT  DHT  DHT  DHT  DHT  DHT  DHT  DHT  DHT  DHT  DHT  vehicle  vehicle  vehicle (A) RNA from fly heads expressing AR using GMR-GAL4 was extracted and analyzed using Affymetrix arrays. Using a false discovery rate of 0.1, 149 genes were identified as showing significant changes in AR52Q flies due to DHT treatment and were thereby selected for further analysis. (B) Scoring of the external eye phenotype shows a correlation between the severity of the observable external phenotype and the clustering results. (C) PCA analysis using the 149 genes shown in (A). See also Figure S6 and Table S1. of assays, the E897K mutation resulted in a stronger suppression than K720A ( Figures 4D, 4E , 4G, and 4H), an observation that is consistent with the stronger AF-2 disruption due to the reversal of charge (E/K) compared to the neutralization of charge (K/A). These results indicate that AF-2 function is essential for polyglutamine-expanded AR toxicity. Importantly, the morphological ( Figure 1J ) and molecular ( Figure 5 ) phenotypes of AR12Q recapitulate those of AR52Q, only less strongly, suggesting that polyglutamine-expanded AR toxicity may be mediated by amplification of wild-type AR function. We conclude that SBMA pathogenesis is mediated by amplification of native AR interactions, and that functions of the AF-2 domain are essential to toxicity.
Although we have demonstrated that polyglutamineexpanded AR toxicity requires DNA binding followed by association with AF-2 coregulators, we do not yet know how this results in toxicity. We favor a model in which the AF-2 domain of AR competes with other transcription factors for a finite supply of coregulators. According to this model, amplification of AR activity could result in reduced availability of coregulators for important functions. This model is consistent with our observation that RNAi-mediated knockdown of AF-2 interactors consistently enhances toxicity. A key outstanding question not answered in this study is how AR activity in the nucleus is amplified. One possibility is that aggregation-prone polyglutamine-expanded AR adopts a toxic conformation that amplifies AF-2-based interactions. However, the fact that we did not detect polyglutamine length-dependent changes in coimmunoprecipitation of AR and FHL2 argues against this possibility ( Figure S8 ). An alternative possibility is that polyglutamine expansion amplifies AR activity (and AF-2 function in particular) independent of any change in the intrinsic ability of AR to interact with coregulators-for example, by reducing the inactivation rate of DNA-bound AR or by reducing the rate of AR nuclear efflux, similar to what has been observed for ataxin-7 (Taylor et al., 2006) . The mechanism by which polyglutamine expansion amplifies AR nuclear activity will be an important focus for future studies. In previous analysis we observed the presence of high molecular weight species of presumed aggregated polyglutamine-expanded AR in our Drosophila model of SBMA (Pandey et al., 2007) . These species are also present in the mutant forms of AR included in the current study. Quantitative analysis shows no correlation between the amount of high molecular weight species and neurodegeneration in this Drosophila model ( Figures S2E and S2F ). While this observation is intriguing, thorough assessment of the relative contributions of aggregation and altered native function will require follow-up studies in mammals. Though our results indicate that AF-2 function is essential to toxicity (Figure 7) , it is likely that multiple native interactions influence the toxicity of polyglutamine-expanded AR, and this is 
(4) substantiated by the results of our genetic screen. For example, AF-1-interacting coregulators Hey and Rbf were found to modify toxicity, indicating that coregulator interactions at AF-1 likely participate in pathogenesis. One of these proteins, Rbf, was also recently shown to modulate the toxicity of polyglutamine-expanded AR in another Drosophila model of SBMA. In this study, Rb was shown to have increased association with polyglutamine-expanded AR, leading to reduced Rb activity and subsequent loss of regulation of Rb-associated genes (Suzuki et al., 2009 ). Such a model may also apply to AF-2-based interactions.
These observations may easily be aligned with recent reports relating to three other polyglutamine diseases in which the data point away from the intrinsic toxicity of expanded polyglutamine and toward the toxic consequences of amplified native interactions. A series of publications from the Orr and Zoghbi labs has illuminated the role of native interactions of ataxin-1 in the pathogenesis of SCA1 (Emamian et al., 2003; Lim et al., 2008; Tsuda et al., 2005) . Specifically, polyglutamine expansion favors interaction with the RNA-binding protein RBM17, contributing to SCA1 neuropathology through a gain-of-function mechanism. Concomitantly, polyglutamine expansion attenuates interaction with Capicua, contributing to SCA1 through a partial loss-offunction mechanism (Lim et al., 2008) . Analogous mechanisms have been implicated in the pathogenesis of SCA7 and SCA17, although less is known about the identity of the native interactions that are key to pathogenesis (Friedman et al., 2007; Helmlinger et al., 2006; McMahon et al., 2005; Palhan et al., 2005) .
Though the AF-2 result is interesting insofar as it highlights a model in which polyglutamine expansion drives toxicity through native function, the greatest significance is that these results reveal an opportunity for therapeutic intervention. An entire therapeutic enterprise has developed around targeting AF-2/coregulator interactions with small molecules in efforts to combat prostate cancer, hyperandrogenic syndromes, and male-pattern baldness, among others (Chang and McDonnell, 2005; Schapira, 2002) . Indeed, the drug ASC-J9 was found to ameliorate neurodegeneration in a mouse model of SBMA and this was attributed to increased degradation of polyglutamineexpanded AR (Yang et al., 2007) . However, in light of our findings it is worth noting that ASC-J9 disrupts the interaction between AF-2 and FxxLF-containing coregulators, suggesting that the beneficial effect of ASC-J9 may represent targeted interruption of AF-2-based interactions that are essential mediators of toxicity (Ohtsu et al., 2002) . Although further studies are required to replicate these results in a mammalian model, our current findings allow for the possibility that SBMA patients will not have to rely on drugs that result in global androgen deprivation, but instead hope for therapeutic agents that will act in motor neurons to specifically target toxic AR interactions. Cloning Mutagenesis (G21E, S210D, A574D, K720A, S790D, and E879K) was performed using Quikchange II XL Mutagenesis Kit (Stratagene). NLS sequences were added to AR using a PCR-based method.
Eye Disc Staining UAS-AR flies were crossed to GMR-GAL4 flies on food with or without 1 mM DHT (Steraloids). Pupal eye discs were dissected and fixed with 4% PFA for 30 min at room temperature. Discs were stained with primary antibody for 16 hr at 4 C and secondary antibody for 1 hr at room temperature. Phalloidin staining (Alexa Fluor 568 Phalloidin, Invitrogen) was performed for 2 hr at room temperature. Discs were washed and embedded using Glycergel (Dako), mounted, and examined by laser scanning confocal microscopy.
Eye Phenotypes UAS-AR flies were crossed to GMR-GAL4 flies at 25 C or 29 C on food containing either 1 mM DHT (Steraloids) or 1% ethanol. Eye phenotypes of anesthetized female flies were evaluated with a Leica MZ APO or M205C stereomicroscope and photographed with a Leica DFC320 digital camera. Blinded scoring of the AR phenotype was performed as previously described (Pandey et al., 2007) .
Fly Stocks
Mutant AR flies were generated by cloning human AR constructs into pUAST. DNA was injected into w 1118 embryos by BestGene Inc. (Chino Hills, CA). At least four independently generated transgenic lines were evaluated for all AR-expressing flies. Classical alleles and deficiency lines [Df(1)sd72b, Df(3R) tll-e, Df(2R)Exel6079, Df(3L)Cat, Df(1)N105, wts [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] , Lmpt
GE27535
, and Dp (3;3)st+g18] were obtained from Bloomington Stock Center (Bloomington, IN). RNAi transgenic lines were obtained from the Vienna Drosophila RNAi Center (Vienna, Austria).
Larval Crawling UAS-AR flies were crossed to D42-GAL4 flies at 25 C on food containing either 1 mM DHT (Steraloids) or 1% ethanol. Larval crawling was performed on a 1% agarose gel in a 245 mm 2 dish with gridlines spaced by 2.5 mm. Wandering third instar larvae were allowed to acclimate for 5 min, and the number of gridlines passed by the posterior end of the larvae in 30 s was counted. Each larva was tested three times.
Luciferase Assays
Luciferase assays were performed in HEK293T cells as previously described (Palazzolo et al., 2007) . Briefly, cells were transfected with indicated AR constructs together with both the luciferase pARE-E1b-Luc and the b-galactosidase pCMVb reporter constructs. AR transactivation was measured in the presence and absence of DHT by luciferase assay and normalized to b-galactosidase activity.
Microarray Gene Expression Profiling Analysis UAS-AR flies were crossed to GMR-GAL4 flies at 29 C on food containing either 1 mM DHT (Steraloids) or 1% ethanol. Heads of 15 female offspring were collected and frozen, and RNA was extracted using TRIzol (Invitrogen).
Details of processing and analysis may be found in Supplemental Information.
Neuromuscular Bouton Counting UAS-AR flies were crossed to OK371-GAL4 flies at 25 C on food containing either 1 mM DHT (Steraloids) or 1% ethanol. Third instar larvae were heat killed, dissected in PBS, and fixed with 4% PFA for 20 min. Primary antibody staining was performed at 4 C overnight and secondary antibody staining was performed at room temperature for 4 hr. After staining, pelts were mounted in Fluoromount-G (SouthernBiotech). Boutons at muscle 4 segments A2-A5 on the right and left side were quantified in the mounted muscle preparations.
RNAi Screen
The list of 73 AR-interacting coregulators was generated through literature review. Orthology prediction for Drosophila orthologs of these coregulators was performed using the HUGO Gene Nomenclature Committee Comparison of Orthology Prediction tool along with PSI-BLAST. RNAi lines were obtained from the Vienna Drosophila RNAi Center. Flies expressing UAS-RNAi were crossed to flies expressing GMR-GAL4; UAS-AR52Q at 29 C on food containing either 1 mM DHT (Steraloids) or 1% ethanol. Eye phenotypes of anesthetized female flies were evaluated with a Leica MZ APO or M205C stereomicroscope and photographed with a Leica DFC320 digital camera.
Salivary Gland Staining UAS-AR flies were crossed to fkh-GAL4 flies at 25 C on food containing either 1 mM DHT (Steraloids) or 1% ethanol. For antibody staining, wandering third instar larvae were collected and salivary glands were dissected into 4% PFA in PBS. Glands were stained with primary antibody for 16 hr at 4 C and secondary antibody for 2 hr at room temperature. For details of fixation and washing, see Supplemental Information. For phalloidin staining, wandering third instar larvae were collected and salivary glands were dissected and stained as previously described (Martin and Baehrecke, 2004) using Texas red phalloidin (Invitrogen). Slides were examined using a Leica DMIRE2 microscope and cell size was determined using phalloidin staining and Slidebook software (Intelligent Imaging Innovations).
Statistics
Statistical comparisons were performed by ANOVA and Tukey HSD Test or Student's t test as appropriate.
Viability UAS-AR flies were crossed to elav-GAL4 flies at 25 C on food containing either 1 mM DHT (Steraloids) or 1% ethanol. Crosses were set up using one female and one male. The number of pupae on the sides of the vial and the surface of the food were counted 16 days after parents were added.
Western Blotting UAS-AR flies were crossed to GMR-GAL4 flies at 29 C. Heads of three female offspring were collected, frozen, and lysed in RIPA buffer (150 mM NaCl, 6 mM Na 2 HPO 4 , 4 mM NaH 2 PO 4 , 2 mM EDTA, 1% NaDOC, 1% Triton X-100, and 0.1% SDS) with protease inhibitors (Roche). The lysate was sonicated, boiled, and run on 7.5% Tris-HCl SDS-PAGE gels (Bio-Rad). Proteins were transferred to nitrocellulose membranes (GE Healthcare) and immunoblotted. Blots were developed using the Odyssey Imaging System (Li-Cor Biosciences). 
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